London
· Delayed Price · Currency is GBP · Price in USD AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of GBP 399.75 million. The enterprise value is 348.55 million.
| Market Cap | 399.75M |
| Enterprise Value | 348.55M |
Important Dates
The next estimated earnings date is Thursday, March 6, 2025.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +5.62% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 18.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 6.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.82 |
| EV / Sales | 7.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.52 |
Financial Position
The company has a current ratio of 10.23, with a Debt / Equity ratio of 4.35.
| Current Ratio | 10.23 |
| Quick Ratio | 10.08 |
| Debt / Equity | 4.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.55 |
| Interest Coverage | -3.72 |
Financial Efficiency
Return on equity (ROE) is -161.81% and return on invested capital (ROIC) is -19.43%.
| Return on Equity (ROE) | -161.81% |
| Return on Assets (ROA) | -17.85% |
| Return on Capital (ROIC) | -19.43% |
| Revenue Per Employee | 364,581 |
| Profits Per Employee | -1.06M |
| Employee Count | 117 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.22% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -26.22% |
| 50-Day Moving Average | 18.28 |
| 200-Day Moving Average | 26.09 |
| Relative Strength Index (RSI) | 49.50 |
| Average Volume (20 Days) | 735 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.42 |
Income Statement
In the last 12 months, AnaptysBio had revenue of GBP 42.66 million and -123.60 million in losses. Loss per share was -4.51.
| Revenue | 42.66M |
| Gross Profit | -72.82M |
| Operating Income | -104.51M |
| Pretax Income | -123.59M |
| Net Income | -123.60M |
| EBITDA | -104.04M |
| EBIT | -104.51M |
| Loss Per Share | -4.51 |
Balance Sheet
The company has 320.91 million in cash and 273.86 million in debt, giving a net cash position of 47.05 million.
| Cash & Cash Equivalents | 320.91M |
| Total Debt | 273.86M |
| Net Cash | 47.05M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 62.95M |
| Book Value Per Share | 2.07 |
| Working Capital | 302.02M |
Cash Flow
In the last 12 months, operating cash flow was -76.86 million and capital expenditures -279,788, giving a free cash flow of -77.14 million.
| Operating Cash Flow | -76.86M |
| Capital Expenditures | -279,788 |
| Free Cash Flow | -77.14M |
| FCF Per Share | n/a |
Margins
Gross margin is -170.72%, with operating and profit margins of -245.01% and -289.75%.
| Gross Margin | -170.72% |
| Operating Margin | -245.01% |
| Pretax Margin | -289.74% |
| Profit Margin | -289.75% |
| EBITDA Margin | -243.91% |
| EBIT Margin | -245.01% |
| FCF Margin | n/a |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.08% |
| Shareholder Yield | -0.08% |
| Earnings Yield | -30.92% |
| FCF Yield | -19.30% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of -0.93. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.93 |
| Piotroski F-Score | n/a |